Effect of incretin-based therapies on cancers of digestive system among 101 595 patients with type 2 diabetes mellitus: a systematic review and network meta-analysis combining 84 trials with a median duration of 30 weeks.

Sanbao ChaiShuqing YuZhirong YangShanshan WuLe GaoHaining WangYuan ZhangSiyan ZhanLinong JiFeng Sun

Published in: BMJ open diabetes research & care (2019)

Moderate to high Grading of Recommendations Assessment, Development and Evaluation evidence suggests that incretin-based therapies were not associated with an increased risk of cancer of digestive system in patients with type 2 diabetes mellitus.

Keyphrases

papillary thyroid
squamous cell
childhood cancer
high intensity
clinical practice
gestational age
young adults